Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
main-content
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2019

15.08.2019 | short review

HIV-triggered lymphoma

verfasst von: Dr. Bernd Lorenz Hartmann, Michèle Desiré Atzl

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Treatment outcomes of AIDS-related lymphomas (acquired immune deficiency syndrome, ARL) have improved, nearing those reported for HIV-negative (human immunodeficiency virus) cohorts; recommended treatment protocols are herewith presented. The diagnostic approach to lymphoma in patients with HIV should include screening for and treatment of concomitant infections attributed to HIV-related immunosuppression. Appropriate antiretroviral treatment with adjustments for potential drug interactions should be initiated urgently, and recommended antibiotic, antifungal and antiviral prophylaxis commenced.
Vorheriger Artikel Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue
Nächster Artikel Cutaneous melanoma—The benefit of screening and preventive measures
Literatur
1.
Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495–e504. PubMedPubMedCentralCrossRef
2.
Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28(6):881–90. PubMedPubMedCentralCrossRef
3.
Hunter NB, Vogt S, Ambinder RF. Treatment of HIV-associated lymphomas: the latest approaches for optimizing outcomes. Oncol (willist Park. 2017;31(12):872–7.
4.
5.
Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hubel K. HIV-associated malignant Lymphoma. Oncol Res Treat. 2017;40(3):82–7. PubMedCrossRef
6.
Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857–64. PubMedPubMedCentralCrossRef
7.
Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62. PubMedPubMedCentralCrossRef
8.
Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, et al. Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):596–604. PubMedPubMedCentralCrossRef
9.
Sathekge M. Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):593–5. PubMedCrossRef
10.
The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909–18.
11.
Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, et al. Survival of AIDS-related diffuse large B‑cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol. 2015;168(6):806–10. PubMedCrossRef
12.
Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–43. PubMedPubMedCentralCrossRef
13.
Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B‑cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–16. PubMedPubMedCentralCrossRef
14.
Wilson WH, Sin-Ho J, Pitcher BN, Hsi ED, Friedberg J, Cheson B, et al. Phase III randomized study of R‑CHOP versus DA-EPOCH‑R and molekular analysis of untreated diffuse large B‑cell Lymphoma: CALGB/alliance 50303. Blood. 2016;128(22):469.
15.
Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–8. PubMedPubMedCentralCrossRef
16.
Xicoy B, Ribera JM, Muller M, Garcia O, Hoffmann C, Oriol A, et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55(10):2341–8. PubMedCrossRef
17.
Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859–64. PubMedCrossRef
18.
Cortes J, Thomas D, Rios A, Koller C, O’Brien S, Jeha S, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492–9. PubMedCrossRef
19.
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25. PubMedPubMedCentralCrossRef
20.
Kaplan L. Human herpesvirus-8: Kaposi sarcoma, multicentric Castelman disease, and primary effusion lymphoma. Hematol Am Soc Hematol Educ Programm. 2013;2013:103–8. CrossRef
21.
Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer. 2007;111(4):224–33. PubMedCrossRef
22.
23.
Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653–9. PubMedCrossRef
24.
El-Ayass W, Yu EM, Karcher DS, Aragon-Ching JB. Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2012;12(2):144–7. PubMedCrossRef
25.
Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948–54. PubMedCrossRef
26.
Terasaki Y, Okumura H, Saito K, Sato Y, Yoshino T, Ichinohasama R, et al. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab. Intern Med. 2008;47(24):2175–8. PubMedCrossRef
27.
Foster WR, Bischin A, Dorer R, Aboulafia DM. Human Herpesvirus type 8‑associated large B‑cell Lymphoma: a nonserous extracavitary variant of primary effusion Lymphoma in an HIV-infected man: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2016;16(6):311–21. PubMedPubMedCentralCrossRef
28.
Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. Aids Patient Care Stds. 2004;18(2):67–73. PubMedCrossRef
29.
Won JH, Han SH, Bae SB, Kim CK, Lee NS, Lee KT, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol. 2006;83(4):328–30. PubMedCrossRef
30.
Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233–42. PubMedPubMedCentralCrossRef
31.
Shah NN, Singavi AK, Harrington A. Daratumumab in primary effusion Lymphoma. N Engl J Med. 2018;379(7):689–90. PubMedCrossRef
32.
Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008;8(5):300–4. PubMedCrossRef
33.
Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001;15(2):280–2. PubMedCrossRef
34.
Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17(12):1849–50. PubMedCrossRef
35.
Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117–23. PubMedCrossRef
36.
Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206. PubMedCrossRef
37.
Wang CC, Thanh C, Gibson EA, Ball-Burack M, Hogan LE, Descours B, et al. Transient loss of detectable HIV‑1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv. 2018;2(23):3479–82. PubMedPubMedCentralCrossRef
38.
39.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. PubMedPubMedCentralCrossRef
40.
Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101(10):4115–21. PubMedCrossRef
41.
Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011;11(2):185–9. PubMedCrossRef
42.
Ibrahim IF, Shapiro GA, Naina HV. Treatment of HIV-associated plasmoblastic lymphoma: a single-center experience with 25 patients. J Clin Oncol. 2014;32:abstr 8583. CrossRef
43.
Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169(3):352–5. PubMedCrossRef
44.
Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease. Leuk Res. 2017;62:12–6. PubMedCrossRef
45.
Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM, Canals C, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27(13):2192–8. PubMedCrossRef
46.
Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113(23):6011–4. PubMedCrossRef
47.
Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7(21):2344–51. PubMedPubMedCentralCrossRef
48.
Metadaten
Titel
HIV-triggered lymphoma
verfasst von
Dr. Bernd Lorenz Hartmann
Michèle Desiré Atzl
Publikationsdatum
15.08.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00518-7

Weitere Artikel der Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019 Zur Ausgabe

short review

Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue

short review

Post San Antonio: immunotherapy, chemotherapy and new combinations

review

Immunosuppression after renal transplantation

short review

ASH 2018—Highlights in Multiple Myeloma

case report

Immunotherapeutic approach to a case of advanced hepatoid adenocarcinoma of the lung

review

PSA screening—a matter of debate?

Version: 0.2148.0